Clinical Trial Update: Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of E/C/F/TAF (Genvoya) in adults co-infected with HIV-1 and hepatitis B virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis B

Drugs mentioned

• Genvoya (elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV, HBV | Phase 3 | Status: COMPLETED | Results posted: 2016-04-04